Table 1. Baseline patients characteristics.
| Clinical features | Total n = 133 |
| Male, n (%) | 100 (75.2%) |
| Age, (years), median IQR | 64.9 [56.61–73.03] |
| Underlying disease, n (%) | |
| Haematological malignancies | 106 (79.6%) |
| Lymphoma | 42 (31.6%) |
| Acute lymphoblastic leukemia | 16 (12%) |
| Myeloma | 10 (7.5%) |
| Others | 38 (28.6%) |
| Allogeneic HSCT | 17 (12.8%) |
| Recent neutropenia (within the past week) | 7 (5.3%) |
| Solid tumor | 27 (20.3%) |
| Exposure to chemotherapy | |
| Anthracyclin | 22 (16.5%) |
| Cytarabin | 13 (9.8%) |
| Fludarabin | 9 (6.8%) |
| Rituximab | 16 (12%) |
| Cyclosphophamide | 21 (15.8%) |
| Methotrexate | 7 (5.2%) |
| Respiratory symptoms, n (%) | |
| Dyspnea | 110 (82.7%) |
| Fever | 132 (99.2%) |
| Cough | 73 (54.8%) |
| Charlson Comorbidty Index | 3 [2–4] |
| Anti-PJP prophylaxis, n (%) | 20 (15%) |
| PJP score > 3 in hematology patients, n (%) | 102 (96.2%) |
| PJP score > 3 in all cohort, n (%) | 129 (97%) |
| Shock at admission, n (%) | 15 (11.3%) |
| Previous cortico-steroid treatment, n (%) | 58 (43.6%) |
| SOFA day 1 | 2 [1–4] |
| SOFA-resp day 1 | 2 [1–2] |
| Time from diagnosis suspicion to PJP- treatment (days) | 1 [0–2] |
| Time from symptom onset to PJP-treatment (days) | 6 [3–10] |
| Time between anti-pneumocystis therapy to EACST (days) | 1 [0–4] |
| Co-infections, n (%) | 65 (48.9%) |
| Bacterial | 34 (25.6%) |
| IFI | 30 (22.5%) |
| Viral | 39 (29.3%) |
| HSV1-HSV2 | 18 (13.5%) |
| Severity of illness, n(%) | |
| ICU admission | 58 (43.6%) |
| IMV | 46 (34.6%) |
| Orotracheal intubation between day 1 and day 5 | 35 (26.3%) |
| VAP, n (%) | 23 (17.6%) |
| Vasopressors | 41 (30.8%) |
| RRT | 18 (13.5%) |
| 30-day mortality | 32 (24.1%) |
| 1-year mortality | 75 (56.4%) |
aMedian (IQR) unless otherwise specified, HSCT = haematopoietic stem cell transplant, PCP = Pneumocystis Jirovecii Pneumonia, PJP-score = Pneumocystis Jirovecii Pneumonia score, SOFA = sequential organ failure assessment score, SOFA-resp = respiratory item of the SOFA score, ACST = adjunctive corticosteroid treatment, IFI = invasive fungal infection, HSV = herpes simplex virus, ICU = intensive care unit, IMV = invasive mechanical ventilation, VAP = Ventilation associated Pneumonia, RRT = Renal replacement therapy.